We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity.
With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. Therefore, we license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. To date, we have generated more than $1.6 billion from the successful execution of this partnership strategy.
Furthermore, as the owner or exclusive licensee of more than 1,600 patents worldwide, we lead the RNA-based therapeutic space. We are continually making improvements to our drug discovery platform and our drugs and expanding our antisense technology to include new opportunities. We look forward to remaining the leader in all aspects of antisense technology advancement.
With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. Therefore, we license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. To date, we have generated more than $1.6 billion from the successful execution of this partnership strategy.
Furthermore, as the owner or exclusive licensee of more than 1,600 patents worldwide, we lead the RNA-based therapeutic space. We are continually making improvements to our drug discovery platform and our drugs and expanding our antisense technology to include new opportunities. We look forward to remaining the leader in all aspects of antisense technology advancement.
Company Growth (employees)
Ionis Pharmaceuticals was founded in 1989 and is headquartered in Carlsbad, US
Key People at Ionis Pharmaceuticals
Stanley Crooke
CEO
Lynne Parshall
COO / CFO
Elizabeth Hougen
Chief Accounting Officer
C. Frank Bennett
Senior Vice President of Research
Sarah Boyce
CBO
Steve Hughes
Chief Clinical Development Officer
Brett P. Monia
Senior Vice President of Antisense Drug Discovery
Ionis Pharmaceuticals Office Locations
Ionis Pharmaceuticals has an office in Carlsbad
Carlsbad, US (HQ)
2855 Gazelle Ct
Ionis Pharmaceuticals Data and Metrics
Ionis Pharmaceuticals Financial Metrics
Ionis Pharmaceuticals's revenue was reported to be $346.6 m in FY, 2016 which is a 22% increase from the previous period.
USD
Revenue (FY, 2016) | 346.6 m |
Revenue growth (FY, 2015 - FY, 2016), % | 22% |
Net income (FY, 2016) | (86.6 m) |
EBIT (FY, 2016) | (46.3 m) |
Market capitalization (20-Jul-2017) | 6.9 b |
Closing share price (20-Jul-2017) | 54.4 |
Cash (31-Dec-2016) | 84.7 m |
Ionis Pharmaceuticals's current market capitalization is $6.9 b.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 147.3 m | 214.2 m | 283.7 m | 346.6 m |
Revenue growth, % | 45% | 32% | 22% | |
General and administrative expense | 48.6 m | |||
Operating expense total | 199 m | 261.9 m | 359.5 m | 392.9 m |
EBIT | (51.7 m) | (47.7 m) | (75.8 m) | (46.3 m) |
EBIT margin, % | (35%) | (22%) | (27%) | (13%) |
Interest expense | 19.4 m | 22.2 m | 36.7 m | 38.8 m |
Income tax expense | 5.9 m | 15.4 m | (372 k) | (2.9 m) |
Net Income | (60.6 m) | (39 m) | (88.3 m) | (86.6 m) |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 160 m | 143 m | 128.8 m | 84.7 m |
Accounts Receivable | 51.1 m | |||
Inventories | 8 m | 6.3 m | 6.9 m | 7.5 m |
Current Assets | 735.5 m | 836.6 m | 837 m | 797.9 m |
PP&E | 86.2 m | 89 m | 90.2 m | 92.8 m |
Total Assets | 847.2 m | 955.8 m | 956.1 m | 912.5 m |
Accounts Payable | 11 m | 18 m | 28.4 m | 21.1 m |
Current Liabilities | 97.8 m | 115.3 m | 148.9 m | 133.8 m |
Total Liabilities | 812.9 m | |||
Additional Paid-in Capital | 1.3 b | 1.2 b | 1.3 b | 1.3 b |
Retained Earnings | (967.6 m) | (1 b) | (1.1 b) | (1.2 b) |
Total Equity | 378.4 m | 257.8 m | 200.8 m | 99.6 m |
Financial Leverage | 2.2 x | 3.7 x | 4.8 x | 9.2 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (60.6 m) | (39 m) | (88.3 m) | (86.6 m) |
Depreciation and Amortization | 6.6 m | 6.4 m | 7 m | 7.5 m |
Inventories | (1.9 m) | 1.7 m | (609 k) | (590 k) |
Accounts Payable | 66 k | 4.8 m | 9.2 m | (10.7 m) |
Cash From Operating Activities | 63.5 m | 6.3 m | 21.1 m | (112.1 m) |
Purchases of PP&E | (1.6 m) | (7.5 m) | (7.7 m) | (7.1 m) |
Cash From Investing Activities | (255.7 m) | (82.8 m) | (60.1 m) | 56.6 m |
Cash From Financing Activities | 227.7 m | 59.6 m | 24.7 m | 11.4 m |
Interest Paid | 6 m | 6.4 m | 6.8 m | 7.3 m |
Income Taxes Paid | (4 m) | 1.1 m |
| Y, 2016 | |
|---|---|
Financial Leverage | 9.2 x |
